For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for subsequent MRD measurements ...

Some people have no symptoms. People diagnosed with blood cancer have a team of doctors, nurses, and technicians who work together to manage their cancer. Many types of leukemia produce no obvious ...

Acute Lymphocytic Leukemia, also known as ALL ... disease also quickly escalates through persistent and worsening symptoms as it infects white blood cells throughout the body.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

IN A breakthrough study, researchers have reported encouraging outcomes using autologous chimeric antigen receptor (CAR) T ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic ...